Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

Sylvia Adams, David W. O'Neill, Daisuke Nonaka, Elizabeth Hardin, Luis Chiriboga, Kimberly Siu, Crystal M. Cruz, Angelica Angiulli, Francesca Angiulli, Erika Ritter, Rose Marie Holman, Richard L. Shapiro, Russell S. Berman, Natalie Berner, Yongzhao Shao, Olivier Manches, Linda Pan, Ralph R. Venhaus, Eric W. Hoffman, Achim JungbluthSacha Gnjatic, Lloyd Old, Anna C. Pavlick, Nina Bhardwaj

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations against the cancer/testis Ag NY-ESO-1 in patients with malignant melanoma. Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod. The regimen was very well tolerated with only mild and transient local reactions and constitutional symptoms. Secondarily, we examined the systemic immune response induced by the imiquimod/NY-ESO-1 combination, and show that it elicited both humoral and cellular responses in a significant fraction of patients. Skin biopsies were assessed for imiquimod's in situ immunomodulatory effects. Compared with untreated skin, topical imiquimod induced dermal mononuclear cell infiltrates in all patients composed primarily of T cells, monocytes, macrophages, myeloid DCs, NK cells, and, to a lesser extent, plasmacytoid DCs. DC activation was evident. This study demonstrates the feasibility and excellent safety profile of a topically applied TLR7 agonist used as a vaccine adjuvant in cancer patients. Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity.

Original languageEnglish (US)
Pages (from-to)776-784
Number of pages9
JournalJournal of Immunology
Volume181
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

imiquimod
Melanoma
Immunization
Vaccines
Dendritic Cells
Proteins
Skin
T-Lymphocytes
Safety
Testicular Neoplasms
Feasibility Studies
Myeloid Cells
Cellular Immunity
Natural Killer Cells
Monocytes
Neoplasms
Vaccination
Macrophages
Biopsy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. / Adams, Sylvia; O'Neill, David W.; Nonaka, Daisuke; Hardin, Elizabeth; Chiriboga, Luis; Siu, Kimberly; Cruz, Crystal M.; Angiulli, Angelica; Angiulli, Francesca; Ritter, Erika; Holman, Rose Marie; Shapiro, Richard L.; Berman, Russell S.; Berner, Natalie; Shao, Yongzhao; Manches, Olivier; Pan, Linda; Venhaus, Ralph R.; Hoffman, Eric W.; Jungbluth, Achim; Gnjatic, Sacha; Old, Lloyd; Pavlick, Anna C.; Bhardwaj, Nina.

In: Journal of Immunology, Vol. 181, No. 1, 01.01.2008, p. 776-784.

Research output: Contribution to journalArticle

Adams, S, O'Neill, DW, Nonaka, D, Hardin, E, Chiriboga, L, Siu, K, Cruz, CM, Angiulli, A, Angiulli, F, Ritter, E, Holman, RM, Shapiro, RL, Berman, RS, Berner, N, Shao, Y, Manches, O, Pan, L, Venhaus, RR, Hoffman, EW, Jungbluth, A, Gnjatic, S, Old, L, Pavlick, AC & Bhardwaj, N 2008, 'Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant', Journal of Immunology, vol. 181, no. 1, pp. 776-784. https://doi.org/10.4049/jimmunol.181.1.776
Adams, Sylvia ; O'Neill, David W. ; Nonaka, Daisuke ; Hardin, Elizabeth ; Chiriboga, Luis ; Siu, Kimberly ; Cruz, Crystal M. ; Angiulli, Angelica ; Angiulli, Francesca ; Ritter, Erika ; Holman, Rose Marie ; Shapiro, Richard L. ; Berman, Russell S. ; Berner, Natalie ; Shao, Yongzhao ; Manches, Olivier ; Pan, Linda ; Venhaus, Ralph R. ; Hoffman, Eric W. ; Jungbluth, Achim ; Gnjatic, Sacha ; Old, Lloyd ; Pavlick, Anna C. ; Bhardwaj, Nina. / Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. In: Journal of Immunology. 2008 ; Vol. 181, No. 1. pp. 776-784.
@article{528ec267faaa4e45a6d4978b014a0257,
title = "Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant",
abstract = "T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations against the cancer/testis Ag NY-ESO-1 in patients with malignant melanoma. Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod. The regimen was very well tolerated with only mild and transient local reactions and constitutional symptoms. Secondarily, we examined the systemic immune response induced by the imiquimod/NY-ESO-1 combination, and show that it elicited both humoral and cellular responses in a significant fraction of patients. Skin biopsies were assessed for imiquimod's in situ immunomodulatory effects. Compared with untreated skin, topical imiquimod induced dermal mononuclear cell infiltrates in all patients composed primarily of T cells, monocytes, macrophages, myeloid DCs, NK cells, and, to a lesser extent, plasmacytoid DCs. DC activation was evident. This study demonstrates the feasibility and excellent safety profile of a topically applied TLR7 agonist used as a vaccine adjuvant in cancer patients. Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity.",
author = "Sylvia Adams and O'Neill, {David W.} and Daisuke Nonaka and Elizabeth Hardin and Luis Chiriboga and Kimberly Siu and Cruz, {Crystal M.} and Angelica Angiulli and Francesca Angiulli and Erika Ritter and Holman, {Rose Marie} and Shapiro, {Richard L.} and Berman, {Russell S.} and Natalie Berner and Yongzhao Shao and Olivier Manches and Linda Pan and Venhaus, {Ralph R.} and Hoffman, {Eric W.} and Achim Jungbluth and Sacha Gnjatic and Lloyd Old and Pavlick, {Anna C.} and Nina Bhardwaj",
year = "2008",
month = "1",
day = "1",
doi = "10.4049/jimmunol.181.1.776",
language = "English (US)",
volume = "181",
pages = "776--784",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

AU - Adams, Sylvia

AU - O'Neill, David W.

AU - Nonaka, Daisuke

AU - Hardin, Elizabeth

AU - Chiriboga, Luis

AU - Siu, Kimberly

AU - Cruz, Crystal M.

AU - Angiulli, Angelica

AU - Angiulli, Francesca

AU - Ritter, Erika

AU - Holman, Rose Marie

AU - Shapiro, Richard L.

AU - Berman, Russell S.

AU - Berner, Natalie

AU - Shao, Yongzhao

AU - Manches, Olivier

AU - Pan, Linda

AU - Venhaus, Ralph R.

AU - Hoffman, Eric W.

AU - Jungbluth, Achim

AU - Gnjatic, Sacha

AU - Old, Lloyd

AU - Pavlick, Anna C.

AU - Bhardwaj, Nina

PY - 2008/1/1

Y1 - 2008/1/1

N2 - T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations against the cancer/testis Ag NY-ESO-1 in patients with malignant melanoma. Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod. The regimen was very well tolerated with only mild and transient local reactions and constitutional symptoms. Secondarily, we examined the systemic immune response induced by the imiquimod/NY-ESO-1 combination, and show that it elicited both humoral and cellular responses in a significant fraction of patients. Skin biopsies were assessed for imiquimod's in situ immunomodulatory effects. Compared with untreated skin, topical imiquimod induced dermal mononuclear cell infiltrates in all patients composed primarily of T cells, monocytes, macrophages, myeloid DCs, NK cells, and, to a lesser extent, plasmacytoid DCs. DC activation was evident. This study demonstrates the feasibility and excellent safety profile of a topically applied TLR7 agonist used as a vaccine adjuvant in cancer patients. Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity.

AB - T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations against the cancer/testis Ag NY-ESO-1 in patients with malignant melanoma. Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod. The regimen was very well tolerated with only mild and transient local reactions and constitutional symptoms. Secondarily, we examined the systemic immune response induced by the imiquimod/NY-ESO-1 combination, and show that it elicited both humoral and cellular responses in a significant fraction of patients. Skin biopsies were assessed for imiquimod's in situ immunomodulatory effects. Compared with untreated skin, topical imiquimod induced dermal mononuclear cell infiltrates in all patients composed primarily of T cells, monocytes, macrophages, myeloid DCs, NK cells, and, to a lesser extent, plasmacytoid DCs. DC activation was evident. This study demonstrates the feasibility and excellent safety profile of a topically applied TLR7 agonist used as a vaccine adjuvant in cancer patients. Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity.

UR - http://www.scopus.com/inward/record.url?scp=47949129948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47949129948&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.181.1.776

DO - 10.4049/jimmunol.181.1.776

M3 - Article

C2 - 18566444

AN - SCOPUS:47949129948

VL - 181

SP - 776

EP - 784

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -